Highlights
1 patentProfile claimed by owner
About
First-in-Class Oral Therapy for Inflammatory Autoimmune Skin Diseases
I-Derm Pharma is developing a first-in-class oral therapy for moderate-to-severe psoriasis. Our proprietary small-molecule family targets an inflammatory pathway and has shown strong preclinical efficacy in chimeric mice with psoriatic human skin grafts, alongside a favorable safety profile. We are advancing our lead candidate toward IND with robust IP and are preparing for next milestones and strategic collaborations.
Identity
| Name | I-Derm Pharma |
|---|---|
| Slug | i-derm-pharma |
| Type / kind | startup |
| Source _id | 12m6BQa4fiGaENYQmLpwhw4FwjqjobL4r5txZc2NETjEOl5Np6bzNT |
Status
| Status | active |
|---|---|
| Last update | 2026-05-17 |
Location
| HQ country code | IL |
|---|---|
| HQ city | Nazareth |
| HQ address | Wadi el-Haj St 13, Nazareth, Israel |
Web & social
| Website | https://www.idermpharma.com/ |
|---|
Classifications
Primary sector Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
BiologicalsMolecules
Target customers
Healthcare & Life SciencesLife Sciences
Business models
B2B2C
Tags
dermatologypharmaceuticalsautoimmune-diseasesoral-drugs
Funding
| Total raised | — |
|---|---|
| Current stage | Pre-Seed |
Raw source document
Show full JSON (0 KB)
{
"0": "s",
"1": "l",
"2": "i",
"3": "m",
"4": "p",
"5": "a",
"6": "g",
"7": "e",
"8": "s",
"9": "_",
"10": "i",
"11": "m",
"12": "p",
"13": "o",
"14": "r",
"15": "t"
}